Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15068150 | 1.00 | CDK8 (0.31) | CDK8ACVR1 | |
| SCHEMBL24471204 | 0.78 | — | — | |
| SCHEMBL15538933 | 0.71 | KDM4E (0.31) | — | |
| SCHEMBL31361322 | 0.69 | — | — | |
| SCHEMBL19792313 | 0.68 | — | — | |
| SCHEMBL26110077 | 0.68 | — | — | |
| SCHEMBL19402522 | 0.67 | CDK8 (0.42) | CDK8ACVR1 | |
| SCHEMBL15068082 | 0.65 | CDK8 (0.38) | CDK8ACVR1 | |
| SCHEMBL30366714 | 0.65 | GAA (0.35) | — | |
| SCHEMBL12182764 | 0.63 | L3MBTL1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-107074824-B | Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer | 基因泰克公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10155764-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3189049-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2016036954-A1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097052-A1 | BROMODOMAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | CDK8 260/4885ACVR1 3791/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | CDK8 260/4885ACVR1 3791/4885 |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | CDK8 3816/4885ACVR1 4704/4885 |
| US-10155764-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC1 | CDK8 3816/4885ACVR1 4704/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | CDK8 260/4885ACVR1 3791/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | CDK8 260/4885ACVR1 3791/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | CDK8 260/4885ACVR1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.